Key regions: Germany, United States, India, Japan, United Kingdom
The demand for Anti-Rheumatic Drugs in Croatia has been on the rise in recent years.
Customer preferences: Patients in Croatia prefer Anti-Rheumatic Drugs due to the high prevalence of rheumatic diseases in the country. These drugs are highly effective in managing the symptoms of rheumatic diseases, which include joint pain, stiffness, and swelling. Patients prefer these drugs because they provide relief from the symptoms of the disease and improve their quality of life.
Trends in the market: The Anti-Rheumatic Drugs market in Croatia has been growing steadily due to the increasing prevalence of rheumatic diseases in the country. The market has been driven by the high demand for these drugs, which has been fueled by the aging population and the increasing awareness of the benefits of these drugs. The market has also been driven by the increasing availability of these drugs in the country.
Local special circumstances: Croatia has a high prevalence of rheumatic diseases, which has been a major driver of the Anti-Rheumatic Drugs market in the country. The country has a high incidence of rheumatoid arthritis, osteoarthritis, and other rheumatic diseases, which has led to the high demand for these drugs. The government has taken steps to improve the availability of these drugs in the country, which has further fueled the growth of the market.
Underlying macroeconomic factors: The growth of the Anti-Rheumatic Drugs market in Croatia has been supported by the overall growth of the pharmaceutical industry in the country. The pharmaceutical industry has been growing steadily in recent years, driven by the increasing demand for healthcare services and the increasing availability of healthcare facilities. The growth of the industry has been supported by the government's efforts to improve the healthcare system in the country. The government has invested in healthcare infrastructure and has taken steps to improve the availability of healthcare services in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
